Diabetes Trial Studies -
www.ClinicalResearch.com
Participate in a New Study That May Help with Diabetes. Learn More. According to the World Health Organization, there are currently 347 million diabetics worldwide, with 90 percent of those people having type II diabetes specifically. It occurs when fat accumulates in places such as muscles, blood vessels and the heart, causing the cells in those areas to no longer be sufficiently responsive to insulin. This insulin resistance, in turn, causes blood glucose levels to rise to dangerous levels. Ultimately, it can result in things such as heart disease, strokes, blindness, kidney failure, and amputations. Fortunately, however, an international team of scientists has just announced a new way of treating the disease. Currently, one of the main ways of treating type II diabetes involves switching the patient to a healthier diet and increasing the amount of exercise they get – the disease is most often caused by obesity. Additionally, oral medication can be used to increase insulin production and the body’s sensitivity to it, or to decrease glucose production. For approximately 30 percent of patients, however, such medication ceases to be effective after a few years, and they end up having to receive regular insulin injections. The new treatment focuses on VEGF-B, a protein within the body that affects how fat is transported and stored. Using an antibody/drug known as 2H10, the scientists were able to block the signaling of VEGF-B in mice and rats, which subsequently kept fat from accumulating in the “wrong” areas of the animals – namely their muscles, blood vessels and hearts. In one experiment, rodents that were bred to develop diabetes were given the antibody before onset of the disease. As a result, they never did develop type II diabetes. In other experiments, regular rats and mice were made to develop the disease, through obesity caused by a fat-rich diet. After receiving 2H10, however, progression of the disease was halted and reversed. “We discovered VEGF-B back in 1995, and since then the VEGF-B project has been a lengthy sojourn in the wilderness, but now we're making one important discovery after the other,” said Prof. Ulf Eriksson of Sweden’s Karolinska Institutet, which is leading the initiative. “In this present study we've shown that VEGF-B inhibition can be used to prevent and treat type II diabetes, and that this can be done with a drug candidate.” A number of other institutions are also involved in the project, including the Ludwig Institute for Cancer Research and the Australian biopharmaceutical company CSL Limited, which is developing the drug. A paper on the research was published this Wednesday in the journal Nature. About the Author3 Comments@Slowburn I agree with this thesis. I've experienced myself that fat accumulates in the wrong places (hips, on spine, etc) if I don't exercise and hardly move at all and that I feel miserable in this state. I don't believe that this fat is mainly a cause but rather a symptom of a metabolic problem. It has already been shown that being fat is not such a big risk factor for those who exercise regularly. I think that there's basically one thing that the evolutionary process was never able to anticipate: the under use of certain biological mechanisms such as the immune system, cardiovascular system, mitochondria, etc. kwarks28th September, 2012 @ 06:31 pm PDT In the USA the DOT and FAA have health issues with commercial drivers and pilots the metabolic issue has been a real problems sedentary daily activity doesn't help. This new drug really sounds great. I was in the RX business a long time and this new drug if it works should have a profound impact on the RX business. Hopefully it will because the RX business has ruined countless lives of people with metabolic issue related diseases . In LTC SNF and RCF the prisons of health care are opportunitys to stop health care industry abuse. It was so disgusting to see the people have no quality of life because they are immobilized to prevent liability from falling and the meds contributed to more attrition. Health care maintenance with this new drug can possibly solve the obesity problem. The crap we eat that has high fructose corn syrup ingredient I believe is the major cause of obesity ought to be banned from commercial use by the FDA. Bryce Guenther1st October, 2012 @ 08:58 am PDT
Copyright © gizmag 2003 - 2012 To subscribe or visit go to: http://www.gizmag.com |
Many years ago a doctor discovered that 90+% of alcoholics drank either gin tonics, vodka tonics, or whiskey tonics and then spent years trying to figure out what it was about quinine that caused alcoholism. It has since been proven that quinine does not cause alcoholism.
A high percentage of people but not all suffering from type II diabetes have a history of being fat before developing the diabetes so clearly being fat causes type II diabetes. I DON'T THINK SO. I find it more likely that both type II diabetes and obesity have a common cause giving a high correlation between being fat and getting type II diabetes.
Slowburn28th September, 2012 @ 03:25 pm PDT